# Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma

> **NCT00581919** · PHASE2 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 32 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bort, Dex, and Dox with ALCAR

## Key facts

- **NCT ID:** NCT00581919
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2010-12
- **Final completion:** 2013-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2019-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00581919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00581919, "Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00581919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*